J W Sweetenham1, B Goldman2, M L LeBlanc2, J R Cook3, R R Tubbs3, O W Press4, D G Maloney4, R I Fisher5, L M Rimsza6, R M Braziel7, E D Hsi3. 1. Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland. Electronic address: sweetej@ccf.org. 2. Southwest Oncology Group Statistical Center, Seattle. 3. Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland. 4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle. 5. Department of Medicine, University of Rochester Cancer, Rochester. 6. Department of Pathology, University of Arizona, Tucson. 7. Department of Pathology, Oregon Health Sciences University, Portland, USA.
Abstract
BACKGROUND: The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy. PATIENTS AND METHODS: Tissue microarrays were constructed from archived tissue obtained from patients on three sequential Southwest Oncology Group (SWOG) trials for FL. All three trials included anthracycline-based chemotherapy. Anti-CD20 monoclonal antibodies were included for patients in the latter two trials. Immunohistochemistry was used to study the number and distribution of cells staining for forkhead box protein P3 (FOXP3) and lymphoma-associated macrophages (LAMs) and the number of lymphoma cells staining for myeloma-associated antigen-1 (MUM-1). Cox proportional hazards regression was used to evaluate the association between marker expression and overall survival (OS). RESULTS: The number or pattern of infiltrating FOXP3 cells and LAMs did not correlate with OS in sequential SWOG studies for FL. The presence of MUM-1 correlated with lower OS for patients who received monoclonal antibody but not for those treated with chemotherapy alone. CONCLUSIONS: Immune cell composition of lymph nodes did not correlate with OS in this analysis of trials in FL. The mechanism of the observed correlation between MUM-1 expression and adverse prognosis in patients receiving monoclonal antibody therapy requires confirmation.
BACKGROUND: The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy. PATIENTS AND METHODS: Tissue microarrays were constructed from archived tissue obtained from patients on three sequential Southwest Oncology Group (SWOG) trials for FL. All three trials included anthracycline-based chemotherapy. Anti-CD20 monoclonal antibodies were included for patients in the latter two trials. Immunohistochemistry was used to study the number and distribution of cells staining for forkhead box protein P3 (FOXP3) and lymphoma-associated macrophages (LAMs) and the number of lymphoma cells staining for myeloma-associated antigen-1 (MUM-1). Cox proportional hazards regression was used to evaluate the association between marker expression and overall survival (OS). RESULTS: The number or pattern of infiltrating FOXP3 cells and LAMs did not correlate with OS in sequential SWOG studies for FL. The presence of MUM-1 correlated with lower OS for patients who received monoclonal antibody but not for those treated with chemotherapy alone. CONCLUSIONS: Immune cell composition of lymph nodes did not correlate with OS in this analysis of trials in FL. The mechanism of the observed correlation between MUM-1 expression and adverse prognosis in patients receiving monoclonal antibody therapy requires confirmation.
Authors: Daphne de Jong; Ad Koster; Anton Hagenbeek; John Raemaekers; Dennis Veldhuizen; Sabien Heisterkamp; Jan Paul de Boer; Martine van Glabbeke Journal: Haematologica Date: 2008-12-04 Impact factor: 9.941
Authors: G Perea; A Altés; S Montoto; A López-Guillermo; E Domingo-Doménech; A Fernández-Sevilla; J M Ribera; J Grau; C Pedro; J Angel Hernández; C Estany; J Briones; R Martino; A Sureda; J Sierra; E Montserrat Journal: Ann Oncol Date: 2005-06-06 Impact factor: 32.976
Authors: Richard I Fisher; Michael LeBlanc; Oliver W Press; David G Maloney; Joseph M Unger; Thomas P Miller Journal: J Clin Oncol Date: 2005-10-17 Impact factor: 44.544
Authors: Oliver W Press; Joseph M Unger; Rita M Braziel; David G Maloney; Thomas P Miller; Michael LeBlanc; Ellen R Gaynor; Saul E Rivkin; Richard I Fisher Journal: Blood Date: 2003-05-08 Impact factor: 22.113
Authors: Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier Journal: Blood Date: 2003-02-06 Impact factor: 22.113
Authors: Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph M Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt Journal: N Engl J Med Date: 2004-11-18 Impact factor: 91.245
Authors: Rita Coutinho; Andrew J Clear; Emanuele Mazzola; Andrew Owen; Paul Greaves; Andrew Wilson; Janet Matthews; Abigail Lee; Rute Alvarez; Maria Gomes da Silva; José Cabeçadas; Donna Neuberg; Maria Calaminici; John G Gribben Journal: Haematologica Date: 2014-11-25 Impact factor: 9.941
Authors: Robert Kridel; Anja Mottok; Pedro Farinha; Susana Ben-Neriah; Daisuke Ennishi; Yvonne Zheng; Elizabeth A Chavez; Hennady P Shulha; King Tan; Fong Chun Chan; Merrill Boyle; Barbara Meissner; Adele Telenius; Laurie H Sehn; Marco A Marra; Sohrab P Shah; Christian Steidl; Joseph M Connors; David W Scott; Randy D Gascoyne Journal: Blood Date: 2015-08-25 Impact factor: 22.113
Authors: Birgitta Sander; Daphne de Jong; Andreas Rosenwald; Wanling Xie; Olga Balagué; Maria Calaminici; Joaquim Carreras; Philippe Gaulard; John Gribben; Anton Hagenbeek; Marie José Kersten; Thierry Jo Molina; Abigail Lee; Santiago Montes-Moreno; German Ott; John Raemaekers; Gilles Salles; Laurie Sehn; Christoph Thorns; Björn E Wahlin; Randy D Gascoyne; Edie Weller Journal: Haematologica Date: 2014-02-07 Impact factor: 9.941
Authors: Jacob P Smeltzer; Jason M Jones; Steven C Ziesmer; Deanna M Grote; Bing Xiu; Kay M Ristow; Zhi Zhang Yang; Grzegorz S Nowakowski; Andrew L Feldman; James R Cerhan; Anne J Novak; Stephen M Ansell Journal: Clin Cancer Res Date: 2014-04-11 Impact factor: 12.531
Authors: Barbara W Grant; Sin-Ho Jung; Jeffrey L Johnson; Lale Kostakoglu; Eric Hsi; John C Byrd; Jeffrey Jones; John P Leonard; S Eric Martin; Bruce D Cheson Journal: Cancer Date: 2013-08-06 Impact factor: 6.860
Authors: Aliyah R Sohani; Matthew J Maurer; Sharmila Giri; Brandelyn Pitcher; Amy Chadburn; Jonathan W Said; Nancy L Bartlett; Myron S Czuczman; Peter Martin; Cara A Rosenbaum; Sin-Ho Jung; John P Leonard; Bruce D Cheson; Eric D Hsi Journal: Am J Surg Pathol Date: 2021-03-01 Impact factor: 6.298